1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: 011 (34) 932746818
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer
Article first published online: 18 SEP 2006
DOI: 10.1002/cncr.22195
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Castellvi, J., Garcia, A., Rojo, F., Ruiz-Marcellan, C., Gil, A., Baselga, J. and Ramon y Cajal, S. (2006), Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer, 107: 1801–1811. doi: 10.1002/cncr.22195
Publication History
- Issue published online: 3 OCT 2006
- Article first published online: 18 SEP 2006
- Manuscript Accepted: 5 JUL 2006
- Manuscript Revised: 1 JUN 2006
- Manuscript Received: 9 MAR 2006
Funded by
- Spanish Ministry of Education. Grant Number: SAF2002-02184
REFERENCES
- 1, . The hallmarks of cancer. Cell. 2000; 100: 57–70.
- 2, , , et al. A census of human cancer genes. Nat Rev Cancer. 2004; 4: 177–183.
- 3, , , et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 2004; 23: 8171–8183.
- 4, , . Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell. 2003; 12: 271–280.
- 5, . Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926–1945.
- 6, , , . Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 2004 19;23: 3138–3144.
- 7, , , , . Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol. 2005; 25: 2558–2572.
- 8, . Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene. 2005; 24: 4839–4850.
- 9, , , , . Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16: 1472–1487.
- 10, , , . The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol. 2001; 21: 743–754.
- 11, , , et al. Epidermal growth-factor receptor expression in normal ovarian epithelium and ovarian-cancer. 1. Correlation of receptor expression with prognostic factors in patients with ovarian-cancer. Am J Obstet Gynecol. 1991; 164: 669–674.
- 12, , , et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004; 15: 104–112.
- 13, , , et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004; 23: 5853–5857.
- 14, , , et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 2004; 10: 6432–6436.
- 15, , , et al. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts. Gene Ther. 2001; 8: 1627–1634.
- 16, , , et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005; 280: 4029–4036.
- 17, , , et al. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Ther. 2003; 10: 152–160.
- 18, . Does the ribosome translate cancer? Nat Rev Cancer. 2003; 3: 179–192.
- 19, . mTOR, translational control and human disease. Semin Cell Dev Biol. 2005; 16: 29–37.
- 20. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med. 2001; 7: 482–484.
- 21, , , et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma—from the Danish “MALOVA” ovarian cancer study. Cancer. 2003; 98: 66–73.Direct Link:
- 22, , , et al. Overexpression of Her-2 neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991; 164: 15–21.
- 23, , , et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer. 2004; 91: 1916–1923.
- 24, , , et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2004; 94: 735–739.
- 25, , , et al. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 2005; 24: 147–152.
- 26, , , et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer. 2004; 91: 470–475.
- 27, , , , . Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004; 14: 1086–1096.Direct Link:
- 28, , , et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000; 19: 2324–2330.
- 29, , . Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005; 23: 1473–1482.
- 30, , , et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004; 10: 6865–6871.
- 31, , , et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004; 64: 5232–5236.
- 32, , , , , . The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004; 204: 93–100.Direct Link:
- 33, , , et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol. 2003; 91: 160–172.
- 34, , , , . Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003; 22: 37–41.
- 35, , , , . Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002; 160: 1223–1228.
- 36, , , et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003; 90: 378–381.
- 37, , , , . Signal pathways involved in activation of p70(S6K) and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem. 2002; 277: 15712–15720.
- 38, , . Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15: 807–826.
- 39, , . The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem. 2002; 277: 11591–11596.
- 40, , . Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med. 2005; 3: 1–11.
- 41, . The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335–348.
- 42, , , et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004; 10: 484–486.
- 43, . Initiation of mRNA translation in oncogenesis—the role of eIF4E. Cell Cycle. 2004; 3: 1387–1389.
- 44, . eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004; 23: 3189–3199.
- 45, , , et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 2004; 5: 553–563.
- 46, , . Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene. 2005; 24: 672–679.
- 47, . Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005; 433: 477–480.